208 related articles for article (PubMed ID: 33392875)
1. Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab.
Sun J; Lepor NE; Cantón G; Contreras L; Hippe DS; Isquith DA; Balu N; Kedan I; Simonini AA; Yuan C; Zhao XQ; Hatsukami TS
Int J Cardiovasc Imaging; 2021 Apr; 37(4):1415-1422. PubMed ID: 33392875
[TBL] [Abstract][Full Text] [Related]
2. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
3. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study.
Nam CW; Kim DS; Li J; Baccara-Dinet MT; Li I; Kim JH; Kim CJ
Korean J Intern Med; 2019 Nov; 34(6):1252-1262. PubMed ID: 30257549
[TBL] [Abstract][Full Text] [Related]
5. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
[TBL] [Abstract][Full Text] [Related]
6. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial.
Ako J; Hibi K; Tsujita K; Hiro T; Morino Y; Kozuma K; Shinke T; Otake H; Uno K; Louie MJ; Takagi Y; Miyauchi K
Circ J; 2019 Sep; 83(10):2025-2033. PubMed ID: 31434809
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
[TBL] [Abstract][Full Text] [Related]
8. Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: A time course study.
Lepor NE; Sun J; Canton G; Contreras L; Hippe DS; Isquith DA; Balu N; Kedan I; Simonini AA; Yuan C; Hatsukami TS; Zhao XQ
Atherosclerosis; 2021 Jun; 327():31-38. PubMed ID: 34038761
[TBL] [Abstract][Full Text] [Related]
9. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
[TBL] [Abstract][Full Text] [Related]
10. Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk.
Ingueneau C; Hollstein T; Grenkowitz T; Ruidavets JB; Kassner U; Duparc T; Combes G; Perret B; Genoux A; Schumann F; Bobbert T; Steinhagen-Thiessen E; Martinez LO
Vascul Pharmacol; 2020 Dec; 135():106804. PubMed ID: 32987194
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
[TBL] [Abstract][Full Text] [Related]
12. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Pradhan AD; Aday AW; Rose LM; Ridker PM
Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
[TBL] [Abstract][Full Text] [Related]
13. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Gallego-Colon E; Daum A; Yosefy C
Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
[TBL] [Abstract][Full Text] [Related]
14. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography.
Gao F; Wang ZJ; Ma XT; Shen H; Yang LX; Zhou YJ
Lipids Health Dis; 2021 Sep; 20(1):106. PubMed ID: 34511134
[TBL] [Abstract][Full Text] [Related]
15. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers.
Hoogeveen RM; Opstal TSJ; Kaiser Y; Stiekema LCA; Kroon J; Knol RJJ; Bax WA; Verberne HJ; Cornel JH; Stroes ESG
JACC Cardiovasc Imaging; 2019 Dec; 12(12):2571-2573. PubMed ID: 31422119
[No Abstract] [Full Text] [Related]
18. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
19. Early decrease in carotid plaque lipid content as assessed by magnetic resonance imaging during treatment of rosuvastatin.
Du R; Cai J; Zhao XQ; Wang QJ; Liu DQ; Leng WX; Gao P; Wu HM; Ma L; Ye P
BMC Cardiovasc Disord; 2014 Jul; 14():83. PubMed ID: 25022285
[TBL] [Abstract][Full Text] [Related]
20. Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
Liang D; Li C; Tu Y; Li Z; Zhang M
Medicine (Baltimore); 2022 Oct; 101(41):e31199. PubMed ID: 36254013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
